無料プレビュー

Spyre Therapeutics, Inc. (SYRE) · NASDAQ Capital Market

プロフィール

Spyre Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for inflammatory bowel disease and immune-mediated diseases. The company's product candidates include SPY001 (α4β7 integrin program), SPY002 (TL1A program), and SPY003 (IL-23 program), all engineered with half-life extension modifications to enable less frequent subcutaneous dosing. Spyre operates a pipeline-focused model with exclusive licenses to intellectual property from Paragon Therapeutics, targeting ulcerative colitis, Crohn's disease, and related conditions.

主要指標

株価: $79.90 (-1.18%)
時価総額: 69億ドル
PER（今期予想）: -29.2
PBR: 6.2
配当利回り: —
52週レンジ: $12.29 – $110.18
業種: Healthcare / Biotechnology
上場: NASDAQ Capital Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-03 · 更新: 2026-10-09